+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biologics Contract Manufacturing Market - Global Forecast to 2030- Product Image
Biologics Contract Manufacturing Market - Global Forecast to 2030- Product Image
Sale

Biologics Contract Manufacturing Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011401
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biologics Contract Manufacturing Market grew from USD 26.53 billion in 2024 to USD 31.04 billion in 2025. It is expected to continue growing at a CAGR of 16.85%, reaching USD 67.56 billion by 2030.

The biologics contract manufacturing sector has evolved into a cornerstone of the global life sciences industry, enabling innovators to accelerate development timelines, optimize production costs and navigate complex regulatory landscapes. As therapeutic proteins, monoclonal antibodies and cell and gene therapies gain traction for treating a spectrum of diseases, strategic outsourcing partnerships are becoming essential. Contract development and manufacturing organizations (CDMOs) offer specialized capabilities ranging from upstream cell culture to downstream purification and fill-finish services. By leveraging advanced bioreactor platforms, modular facilities and integrated quality systems, they empower pharma and biotech firms to scale from clinical trials through commercialization with greater agility. This report examines the forces reshaping contract biologics manufacturing, exploring market dynamics, regulatory shifts and emerging technologies that will define competitive advantage in the years ahead.

Transformative Shifts Redefining Manufacturing Models

Over the past decade, the biologics manufacturing landscape has undergone transformative shifts driven by scientific breakthroughs and evolving stakeholder expectations. The rise of personalized and precision therapies has elevated demand for small-batch, adaptable production lines capable of handling individualized cell and gene therapies. Concurrently, digital process analytics and automation have reduced cycle times while enhancing product consistency. Biosimilar development has surged as regulatory frameworks in major markets encourage cost-effective alternatives to originator biologics. Strategic alliances between innovator companies and CDMOs are now commonplace, with partners co-investing in next-generation continuous processing platforms. Additionally, sustainability imperatives are prompting firms to adopt single-use systems and green chemistry practices. These converging trends compel service providers to reinvent traditional models, integrating end-to-end digital workflows, flexible facility designs and collaborative business structures to capture emerging growth opportunities.

Assessing the Cumulative Impact of U.S. Tariff Adjustments

Beginning in 2025, the United States will implement revised tariff schedules that directly target critical raw materials and single-use consumables used in biologics manufacturing. These levies are expected to increase input costs and create supply chain volatility, particularly for bioreactors, chromatography resins and specialized media imported from Asia and Europe. Manufacturers face a cumulative 5-10% cost escalation, exerting pressure on margins and contract negotiations. To mitigate these impacts, CDMOs and their clients must reassess supplier footprints, diversify procurement channels and negotiate long-term supply agreements that lock in favorable pricing. The tariff environment also underscores the value of localizing critical production steps domestically or nearshore. Firms that proactively invest in regional manufacturing hubs and raw material inventory management will secure more resilient operations in the face of geopolitical uncertainty and evolving trade policies.

Key Segmentation Insights Across the Biologics Value Chain

A nuanced segmentation framework reveals how demand drivers, technological requirements and regulatory considerations differ across product types, applications, production scales, end-user profiles and workflow steps. When examining biologics by type, drug substances such as monoclonal antibodies and therapeutic proteins remain the backbone of CDMO offerings, yet cellular therapies and vaccines are growing at a faster pace due to immuno-oncology and pandemic preparedness initiatives. Within biosimilars, analog biologics and bio-betters capture premium margins through differentiated clinical profiles, while generic biologics focus on cost-effective, high-volume manufacturing. Finished dosage forms demand specialized sterile injectable expertise, complemented by oral and topical formulations for niche indications. On the product type axis, the intricate requirements of gene therapy-whether ex-vivo CAR-T or in-vivo viral vectors-contrast with the large-scale fermentations of recombinant proteins such as insulin and erythropoietin. Cell culture remains the dominant upstream technology, with mammalian systems leading but microbial and yeast platforms offering faster turnaround and lower costs for smaller proteins. Application segmentation highlights surging demand for diagnostic reagents in in-vitro and in-vivo assays, expanding vaccination programs under prophylactic mandates, and therapeutic biologics targeting cardiovascular, autoimmune, neurology and oncology indications. Production scale considerations drive facility design choices: pilot-scale lines for early-stage development, clinical-scale suites for Phase I/II trials and commercial-scale plants for global supply. Academia and research organizations invest in small-batch capabilities for proof-of-concept studies, biotechnology firms partner on flexible development runs, government and health institutions accelerate pandemic-response vaccines, and large pharma companies leverage high-throughput commercial lines to sustain blockbuster biologics. Workflow steps form the backbone of service delivery: upstream activities from media preparation and bioreactor operation to cell separation demand robust process controls, process development services including formulation, fill-finish and filtration ensure product stability, and downstream operations such as buffer exchange, chromatography and final filtration deliver purification at high yield and quality. Understanding these intersecting dimensions enables stakeholders to tailor service portfolios, optimize capacity utilization and anticipate unmet needs in the evolving biologics ecosystem.

Key Regional Insights Shaping Capacity and Demand

Regional dynamics in biologics contract manufacturing reflect variations in regulatory frameworks, infrastructure maturity and cost structures. In the Americas, strong biotech clusters in the United States and Canada drive sustained demand for end-to-end CDMO services, supported by advanced single-use technologies and robust quality oversight. Latin American markets are beginning to adopt local fill-finish and pilot-scale capabilities, driven by government incentives to reduce reliance on imports. Across Europe, Middle East and Africa, capacity expansions are concentrated in Western Europe, leveraging established GMP ecosystems and proximity to major pharma clients, while the Gulf Cooperation Council and South Africa invest in scalable modular facilities to address vaccine and therapeutic shortages. The Asia-Pacific region exhibits the fastest growth, with China and India emerging as global contract hubs through large-scale mammalian cell culture plants, integrated gene therapy platforms and competitive cost advantages. Regulatory harmonization efforts, such as ICH Q5A alignment, are facilitating cross-border manufacturing partnerships and accelerating product approvals across the region.

Key Company Insights and Strategic Moves

Leading CDMOs and pharmaceutical partners are driving innovation through strategic investments, capacity expansions and technology licensing agreements. AbbVie’s collaboration with external biologics specialists streamlines monoclonal antibody production, while Abzena’s modular facilities support rapid scale-up for peptide and antibody-drug conjugate pipelines. Acino International AG leverages its global footprint to offer end-to-end services, complemented by ADMA Biologics’ focus on plasma-derived therapeutics. AGC Biologics has strengthened its bioreactor portfolio, integrating single-use and stainless-steel systems to serve diverse client needs. Ajinomoto Bio-Pharma Services has enhanced its gene therapy manufacturing through media optimization and vector production platforms. Avid Bioservices and Baxter International are expanding fill-finish capacity to meet injectable demand, while Boehringer Ingelheim Biopharmaceuticals champions continuous processing in Europe. Cambrex Corporation and Catalent are investing in cell culture and viral vector capabilities, respectively, to capture emerging clinical projects. Emergent BioSolutions continues to scale vaccine contract manufacturing, and FUJIFILM Diosynth Biotechnologies has broadened its recombinant protein suite. JSR Life Sciences is integrating chromatographic resins with downstream solutions, and Kemwell Biopharma is boosting pilot-scale capacity in India. Lonza Group remains a market leader with broad service offerings across all workflow steps, paralleled by Midas Pharma’s niche expertise in oral and topical formulations. ProBioGen AG and Recipharm AB exemplify specialized service models for cell therapy and fill-finish, while Rentschler Biopharma focuses on high-yield upstream processing. Samsung Biologics, Thermo Fisher Scientific and Toyobo Co. continue to expand global manufacturing parks, and Wacker Chemie AG has enhanced its fermentation and purification technologies. WuXi Biologics maintains a dominant position in Asia-Pacific with vertically integrated platforms spanning discovery through commercial supply. These collective moves underscore a race to build flexible, scalable networks that cater to diverse therapeutic modalities.

Actionable Recommendations for Future-Proofed Growth

To navigate the evolving biologics landscape, industry leaders should prioritize investments in modular, single-use facilities and continuous processing systems that support small-batch and large-scale production alike. Establishing dual-source supply agreements for critical consumables and raw materials will mitigate tariff-induced cost pressures and safeguard operations. Strategic collaborations with technology vendors can accelerate digitalization initiatives, integrating real-time analytics for process monitoring and predictive maintenance. Cultivating regulatory expertise across emerging markets and leveraging harmonized guidelines will streamline cross-border approvals. Additionally, developing flexible workforce capabilities-combining specialized bioprocess engineers with agile project management teams-will enhance responsiveness to client needs. Finally, exploring regional manufacturing hubs near key end markets can reduce lead times, lower logistics costs and fortify resilience against geopolitical disruptions.

Conclusion and Outlook for Contract Biomanufacturing

The biologics contract manufacturing sector stands at a pivotal juncture, balancing unprecedented therapeutic innovation with complex operational and regulatory challenges. By understanding segmentation nuances, regional dynamics and competitive strategies, stakeholders can make informed decisions that drive efficiency, quality and scalability. Embracing flexible manufacturing platforms, fostering collaborative partnerships and proactively managing supply chain risks will be critical to capturing emerging opportunities in cell and gene therapies, biosimilars and beyond. As the industry continues to evolve, CDMOs and their clients must remain adaptable, investing in the right technologies and capabilities to sustain long-term success.

Market Segmentation & Coverage

This research report categorizes the Biologics Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Biologics Drug Substance
    • Cellular Therapies
    • Monoclonal Antibodies
    • Therapeutic Proteins
    • Vaccines
  • Biosimilars
    • Analog Biologics
    • Bio-Betters
    • Generic Biologics
  • Finished Dosage Forms
    • Injectable
    • Oral
    • Topical
  • Cell Culture
    • Mammalian Cell Culture
    • Microbial Fermentation
    • Yeast Fermentation
  • Gene Therapy
    • Ex-Vivo
    • In-Vivo
  • Recombinant Proteins
    • Erythropoietin
    • Insulin
    • Interferon
  • Diagnostic
    • In-Vitro
    • In-Vivo
  • Prophylactic
    • Preventive Treatments
    • Vaccination Programs
  • Therapeutic
    • Cardiovascular Disease
    • Inflammatory and Autoimmune Disorders
    • Neurology
    • Oncology
  • Clinical Scale
  • Commercial Scale
  • Pilot Scale
  • Academia
  • Biotechnology Firms
  • Government and Health Institutions
  • Pharmaceutical Companies
  • Research Organizations
  • Downstream
    • Buffer Exchange
    • Chromatography
    • Filtration
  • Process Development
    • Fill and Finish
    • Formulation and Filtration
  • Upstream
    • Bioreactor Operation
    • Cell Separation
    • Media Preparation

This research report categorizes the Biologics Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Biologics Contract Manufacturing Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie, Inc.
  • Abzena Ltd.
  • Acino International AG
  • ADMA Biologics, Inc.
  • AGC Biologics
  • Ajinomoto Bio-Pharma Services
  • Avid Bioservices, Inc.
  • Baxter International, Inc
  • Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
  • Cambrex Corporation
  • Catalent, Inc.
  • Emergent BioSolutions, Inc.
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
  • JSR Life Sciences, LLC by JSR Group
  • Kemwell Biopharma Pvt. Ltd.
  • Lonza Group Ltd.
  • Midas Pharma GmbH
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co. Ltd.
  • Wacker Chemie AG
  • WuXi Biologics Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biologics Contract Manufacturing Market, by Type
8.1. Introduction
8.2. Biologics Drug Substance
8.2.1. Cellular Therapies
8.2.2. Monoclonal Antibodies
8.2.3. Therapeutic Proteins
8.2.4. Vaccines
8.3. Biosimilars
8.3.1. Analog Biologics
8.3.2. Bio-Betters
8.3.3. Generic Biologics
8.4. Finished Dosage Forms
8.4.1. Injectable
8.4.2. Oral
8.4.3. Topical
9. Biologics Contract Manufacturing Market, by Product Type
9.1. Introduction
9.2. Cell Culture
9.2.1. Mammalian Cell Culture
9.2.2. Microbial Fermentation
9.2.3. Yeast Fermentation
9.3. Gene Therapy
9.3.1. Ex-Vivo
9.3.2. In-Vivo
9.4. Recombinant Proteins
9.4.1. Erythropoietin
9.4.2. Insulin
9.4.3. Interferon
10. Biologics Contract Manufacturing Market, by Application
10.1. Introduction
10.2. Diagnostic
10.2.1. In-Vitro
10.2.2. In-Vivo
10.3. Prophylactic
10.3.1. Preventive Treatments
10.3.2. Vaccination Programs
10.4. Therapeutic
10.4.1. Cardiovascular Disease
10.4.2. Inflammatory and Autoimmune Disorders
10.4.3. Neurology
10.4.4. Oncology
11. Biologics Contract Manufacturing Market, by Production Scale
11.1. Introduction
11.2. Clinical Scale
11.3. Commercial Scale
11.4. Pilot Scale
12. Biologics Contract Manufacturing Market, by End-User
12.1. Introduction
12.2. Academia
12.3. Biotechnology Firms
12.4. Government and Health Institutions
12.5. Pharmaceutical Companies
12.6. Research Organizations
13. Biologics Contract Manufacturing Market, by Workflow Step
13.1. Introduction
13.2. Downstream
13.2.1. Buffer Exchange
13.2.2. Chromatography
13.2.3. Filtration
13.3. Process Development
13.3.1. Fill and Finish
13.3.2. Formulation and Filtration
13.4. Upstream
13.4.1. Bioreactor Operation
13.4.2. Cell Separation
13.4.3. Media Preparation
14. Americas Biologics Contract Manufacturing Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Biologics Contract Manufacturing Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Biologics Contract Manufacturing Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie, Inc.
17.3.2. Abzena Ltd.
17.3.3. Acino International AG
17.3.4. ADMA Biologics, Inc.
17.3.5. AGC Biologics
17.3.6. Ajinomoto Bio-Pharma Services
17.3.7. Avid Bioservices, Inc.
17.3.8. Baxter International, Inc
17.3.9. Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
17.3.10. Cambrex Corporation
17.3.11. Catalent, Inc.
17.3.12. Emergent BioSolutions, Inc.
17.3.13. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
17.3.14. JSR Life Sciences, LLC by JSR Group
17.3.15. Kemwell Biopharma Pvt. Ltd.
17.3.16. Lonza Group Ltd.
17.3.17. Midas Pharma GmbH
17.3.18. ProBioGen AG
17.3.19. Recipharm AB
17.3.20. Rentschler Biopharma SE
17.3.21. Samsung Biologics
17.3.22. Thermo Fisher Scientific, Inc.
17.3.23. Toyobo Co. Ltd.
17.3.24. Wacker Chemie AG
17.3.25. WuXi Biologics Co., Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BIOLOGICS CONTRACT MANUFACTURING MARKET MULTI-CURRENCY
FIGURE 2. BIOLOGICS CONTRACT MANUFACTURING MARKET MULTI-LANGUAGE
FIGURE 3. BIOLOGICS CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY WORKFLOW STEP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY WORKFLOW STEP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. BIOLOGICS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. BIOLOGICS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOLOGICS CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS DRUG SUBSTANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELLULAR THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS DRUG SUBSTANCE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALOG BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIO-BETTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENERIC BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MICROBIAL FERMENTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY YEAST FERMENTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY EX-VIVO, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INTERFERON, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINATION PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFLAMMATORY AND AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL SCALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PILOT SCALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ACADEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AND HEALTH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY WORKFLOW STEP, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BUFFER EXCHANGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL AND FINISH, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION AND FILTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL SEPARATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MEDIA PREPARATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS DRUG SUBSTANCE, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY WORKFLOW STEP, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS DRUG SUBSTANCE, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY WORKFLOW STEP, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS DRUG SUBSTANCE, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY WORKFLOW STEP, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 133. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 134. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS DRUG SUBSTANCE, 2018-2030 (USD MILLION)
TABLE 135. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 136. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 137. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 138. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 139. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 140. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 141. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 143. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 144. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 145. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 146. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY WORKFLOW STEP, 2018-2030 (USD MILLION)
TABLE 148. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 149. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 150. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 151. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 152. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS DRUG SUBSTANCE, 2018-2030 (USD MILLION)
TABLE 153. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 154. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 155. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 156. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 157. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 158. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 159. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 161. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 162. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 163. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 164. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY WORKFLOW STEP, 2018-2030 (USD MILLION)
TABLE 166. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 167. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 168. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS DRUG SUBSTANCE, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY WORKFLOW STEP, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS DRUG SUBSTANCE, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY WORKFLOW STEP, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS DRUG SUBSTANCE, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 217. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 219. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 220. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY WORKFLOW STEP, 2018-2030 (USD MILLION)
TABLE 222. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 223. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 225. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 226. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS DRUG SUBSTANCE, 2018-2030 (USD MILLION)
TABLE 227. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 228. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 229. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 230. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 231. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 232. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 233. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 234. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 235. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 236. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 237. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 238. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 239. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY WORKFLOW STEP, 2018-2030 (USD MILLION)
TABLE 240. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 241. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 242. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 243. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 244. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS DRUG SUBSTANCE, 2018-2030 (USD MILLION)
TABLE 245. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 246. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 247. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 249. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 250. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 251. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 253. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 254. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 255. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 256. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 257. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY WORKFLOW STEP, 2018-2030 (USD MILLION)
TABLE 258. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 259. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 260. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 261. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 262. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS DRUG SUBSTANCE, 2018-2030 (USD MILLION)
TABLE 263. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 264. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 265. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 266. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 267. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 268. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 269. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 273. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY WORKFLOW STEP, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 279. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 280. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS DRUG SUBSTANCE, 2018-2030 (USD MILLION)
TABLE 281. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 282. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 283. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 284. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 285. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 286. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 287. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 289. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 290. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 291. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 292. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 293. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY WORKFLOW STEP, 2018-2030 (USD MILLION)
TABLE 294. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 295. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 296. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS DRUG SUBSTANCE, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE,

Companies Mentioned

  • AbbVie, Inc.
  • Abzena Ltd.
  • Acino International AG
  • ADMA Biologics, Inc.
  • AGC Biologics
  • Ajinomoto Bio-Pharma Services
  • Avid Bioservices, Inc.
  • Baxter International, Inc
  • Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
  • Cambrex Corporation
  • Catalent, Inc.
  • Emergent BioSolutions, Inc.
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
  • JSR Life Sciences, LLC by JSR Group
  • Kemwell Biopharma Pvt. Ltd.
  • Lonza Group Ltd.
  • Midas Pharma GmbH
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co. Ltd.
  • Wacker Chemie AG
  • WuXi Biologics Co., Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report by Source, Service (Process Development), Drug Type (Biologics, Biosimilars), Type, Scale of Operation, Therapeutic Area, Region, and Segment Forecasts, 2025-2030 - Product Image

Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report by Source, Service (Process Development), Drug Type (Biologics, Biosimilars), Type, Scale of Operation, Therapeutic Area, Region, and Segment Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Biologics Contract Development & Manufacturing Organization Market - Global Forecast to 2030 - Product Image

Biologics Contract Development & Manufacturing Organization Market - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 180 Pages
  • Global
From
Biologics Contract Development Market - Global Forecast to 2030 - Product Image

Biologics Contract Development Market - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Biologics Fill Finish Services Market: Industry Trends and Global Forecasts to 2035 - Product Image

Biologics Fill Finish Services Market: Industry Trends and Global Forecasts to 2035

  • Report
  • 470 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.